Subscribe to Newsletter
Inside the Lab Precision medicine, Genetics and epigenetics, Oncology, Clinical care

Prognostic Tumor Gene Test for Ovarian Cancer

Credit: UNSW.

Survival rates in patients with epithelial ovarian cancer are poor, with high-grade serous ovarian cancer (HGSOC) accounting for around two-thirds of cases and most deaths. To offer patients a better chance of survival, we need biomarkers that provide insight into prognosis and personalized treatment options. Could gene expression biomarkers be the answer?

Until recently, gene expression findings in HGSOC were inconsistent and presented logistical barriers when using fresh frozen tissue, limiting real-world application. Now, researchers from UNSW Medicine have developed a robust and clinically relevant measure to identify ovarian cancer patients with poor prognosis using formalin-fixed, paraffin-embedded (FFPE) tumor tissue (1).

By analyzing 3,769 ovarian cancer tumor samples from the Ovarian Tumour Tissue Analysis (OTTA) consortium, they found that gene expression could reliably predict a patient’s chance of surviving five years after diagnosis, with a difference of seven years’ survival between poor and good prognosis groups. The signature was an even better predictor than age or stage of disease alone. “We were surprised at how well the assays worked on RNA from old FFPE tumor tissue blocks,” says Susan Ramus, co-founder of the OTTA consortium and lead researcher on the study.

In the clinic, the new test would enable more informed, personalized treatment decisions. Ramus says, “As patients are diagnosed with ovarian cancer, their tumors could be tested for this signature, and those predicted to have poor survival with current treatments could rapidly be included in clinical trials of alternative treatments.”

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. J Millstein et al., Ann Oncol, 31, 1240 (2020). PMID: 32473302.
About the Author
Liv Gaskill

During my undergraduate degree in psychology and Master’s in neuroimaging for clinical and cognitive neuroscience, I realized the tasks my classmates found tedious – writing essays, editing, proofreading – were the ones that gave me the greatest satisfaction. I quickly gathered that rambling on about science in the bar wasn’t exactly riveting for my non-scientist friends, so my thoughts turned to a career in science writing. At Texere, I get to craft science into stories, interact with international experts, and engage with readers who love science just as much as I do.

Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine